ALS Detection: Neurofilament Light Chain Biomarker
- A blood-based biomarker could help clinicians detect and treat amyotrophic lateral sclerosis (ALS) earlier.
- Bornhorst,PhD,of the Mayo Clinic,discussed the latest biomarker detection technology and its potential for ALS patients.
- Bornhorst noted that blood tests are appealing for evaluating potential ALS cases, complementing clinical and imaging studies.
Early detection of ALS is within reach, thanks to the promising NfL biomarker. This breakthrough in neurodegenerative disease diagnosis, highlighted by News Directory 3, offers the potential for earlier interventions and improved patient outcomes. Discover how neurofilament light chain (NfL) blood tests are revolutionizing ALS detection by assessing neuronal damage with remarkable accuracy, approximately 90% in studies. Explore expert insights on the critical role of neurological biomarkers and the importance of specialist interpretation to get the most out of this testing. Learn about ongoing research on NfL’s diagnostic capabilities and its integration into clinical practice. Discover what’s next in the future of ALS diagnosis and treatment.
NfL Biomarker Shows Promise in ALS Detection,early Diagnosis
Updated May 27,2025
A blood-based biomarker could help clinicians detect and treat amyotrophic lateral sclerosis (ALS) earlier. ALS, a neurodegenerative condition, impairs muscle control and executive function.
Joshua A. Bornhorst,PhD,of the Mayo Clinic,discussed the latest biomarker detection technology and its potential for ALS patients.
Bornhorst noted that blood tests are appealing for evaluating potential ALS cases, complementing clinical and imaging studies. He emphasized that specialists should carefully consider diagnoses, making rapid, in-office testing unnecessary.
According to Bornhorst, neurofilament light chain (NfL) is a promising blood-based assay for assessing neuronal damage in neurodegenerative disorders.Plasma NfL testing has been clinically available for several years at Mayo Clinic Laboratories.
NfL, a nonspecific marker of neuronal damage, has been evaluated globally as a potential diagnostic and prognostic tool for various neurodegenerative diseases, including multiple sclerosis, frontotemporal dementia, Parkinson’s, and Alzheimer’s disease. While not the most effective diagnostic marker for some conditions like alzheimer’s, recent research indicates NfL remains a frontrunner for ALS diagnosis.
Effective analytic testing for NfL has been demonstrated,but other neurological disorders,such as traumatic brain injury and concussion,can also elevate NfL levels. Studies suggest NfL blood testing for ALS has about 90% accuracy; however, this may vary across populations. Further research is needed to determine if NfL can be considered diagnostic, as numerous non-ALS factors can alter its concentration. It will likely need to be used with other clinical, imaging, and biomarkers.
Bornhorst believes effective NfL use will require a physician familiar with neurological biomarkers, such as a neurologist.Widespread use and reimbursement will depend on increasing comfort with diagnostic results and incorporating NfL testing into professional guidelines.
Early detection of ALS and its underlying pathology is valuable because some treatments can slow the disease’s progression. NfL also provides insight into prognosis and disease progression. Multiple NfL measurements over time may help monitor and adjust treatments, possibly improving the quality of life for ALS patients.
Recent progress in Alzheimer’s disease diagnosis and treatments, spurred by effective blood marker tests like p-tau217, demonstrates the importance of diagnostic testing in advancing treatment. The hope is that this will also be the case for ALS.
What’s next
Further studies are needed to refine the use of neurofilament light chain (NfL) as a reliable biomarker for ALS detection and to integrate it effectively into clinical practice for improved patient outcomes.